PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC ANAL CANCER OR HPV+ SQUAMOUS CELL CANCER OF THE RECTUM
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Anal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FAWCETT
- Sponsors Advaxis
- 13 Jun 2017 Results from Stage 1 published in an Advaxis Media Release
- 13 Jun 2017 According to an Advaxis media release, Dr. Eng is the principal investigator of this study.
- 13 Jun 2017 According to an Advaxis media release, an update from this trial presented at annual Investor & Analyst Day.